Wells Fargo analyst David Maris maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) today. The company’s shares closed yesterday at $176.29, close to its 52-week high of $184.
According to TipRanks.com, Maris has 0 stars on 0-5 star ranking scale with an average return of -4.3% and a 40.9% success rate. Maris covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Amphastar Pharmaceuticals, and Kala Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Jazz Pharmaceuticals with a $202.42 average price target, representing a 14.8% upside. In a report issued on August 8, BMO Capital also maintained a Buy rating on the stock with a $206 price target.
.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals’ market cap is currently $10.65B and has a P/E ratio of 24.93. The company has a Price to Book ratio of 3.71.
Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. Earlier this month, Rick Winningham, a Director at JAZZ sold 16,639 shares for a total of $2,931,292.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.
